I attended National Health IT Week in Washington DC. There were a number of seminars and meetings focused on the growth of health IT in the United States.
Today’s medical device data is far more likely to be inaccurate, unclear, and unreliable. And that’s entirely unacceptable when you consider the vast range of users who rely on this knowledge to identify, source, manage, document, track, and bill for millions of device options.
We recently interviewed FDB's Director of Software Engineering Joshua Young about the application of artificial intelligence in healthcare. What follows are highlights from that interview.
Curiously, the FDA seems to be undercutting its own cost savings efforts through its support of a rule that would require unique non-proprietary names with four-character suffixes for biosimilar products. The problem is this proposed naming convention is simply not necessary and could do more harm than good.
Our society’s focus on natural and organic products that promote health has directed scrutiny to chemicals used as preservatives. What is the issue with preservatives?
Any baseball player will tell you how difficult it is to ensure that the ball hits the “sweet spot” on the bat. But their troubles pale in comparison to health system supply chain or value analysis committees.
Be notified about new FDB Blog posts as they are published by submitting the information below. (If you are already an FDB Customer in North America, you are automatically receiving blog updates by email and do not need to sign up.)
Strategic Alliances Director
Director, Software Development
VP, Health Policy
Strategy and Innovation, CCI
Manager, Consumer Drug Info
Senior VP and Editorial Director
Associate Product Manager
Howell, MD, PhD
VP, Clinical Applications